Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206992 | 0.93 | S1PR1 (0.56) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3223933 | 0.83 | S1PR1 (0.53) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1424823 | 0.82 | S1PR1 (0.51) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3276153 | 0.79 | S1PR1 (0.51) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3211925 | 0.79 | S1PR1 (0.59) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3218653 | 0.79 | S1PR1 (0.50) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL3210925 | 0.79 | S1PR1 (0.59) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1425230 | 0.78 | S1PR1 (0.53) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1425248 | 0.78 | S1PR1 (0.53) | S1PR1S1PR3S1PR5 | |
| SCHEMBL1424762 | 0.77 | S1PR1 (0.52) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| CN-101511827-B | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-01 | — | — | CN | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| CN-101511827-A | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2069336-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | S1PR1 96/4885S1PR3 102/4885S1PR5 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.